LON:HIK Hikma Pharmaceuticals (HIK) Share Price, News & Analysis GBX 1,682 +5.00 (+0.30%) As of 12:42 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsInsider TradesNews and Trends About Hikma Pharmaceuticals Stock (LON:HIK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Hikma Pharmaceuticals alerts:Sign Up Key Stats Today's Range 1,667▼ 1,68650-Day Range 1,498▼ 1,75152-Week Range 1,187▼ 1,762Volume18.55 million shsAverage Volume4.47 million shsMarket Capitalization£3.48 billionP/E Ratio9.56Dividend Yield3.94%Price TargetGBX 1,986.25Consensus RatingBuy Company Overview At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing facilities, 9 R&D centres and 9,500 employees worldwide. Read More Hikma Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreHIK MarketRank™: 3.202969640725 of 5 starsHikma Pharmaceuticals scored higher than 64% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingHikma Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and no sell ratings.Upside PotentialHikma Pharmaceuticals has a consensus price target of GBX 1,986.25, representing about 18.1% upside from its current price of GBX 1,682.Amount of Analyst CoverageHikma Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Hikma Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Hikma Pharmaceuticals is 9.56, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Hikma Pharmaceuticals is 9.56, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.16.Price to Earnings Growth RatioHikma Pharmaceuticals has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHikma Pharmaceuticals has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for HIK. Dividend2.5 / 5Dividend StrengthModerate Dividend LeadershipHikma Pharmaceuticals is a leading dividend payer. It pays a dividend yield of 3.94%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthHikma Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Hikma Pharmaceuticals is 46.87%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Hikma Pharmaceuticals' dividend. News and Social Media1.2 / 5News Sentiment-0.06 News SentimentHikma Pharmaceuticals has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Hikma Pharmaceuticals this week, compared to 2 articles on an average week. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Hikma Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders22.26% of the stock of Hikma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.62% of the stock of Hikma Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Hikma Pharmaceuticals' insider trading history. Receive HIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HIK Stock News HeadlinesTop 3 British Biotech Stocks To Watch In November 2026November 14 at 7:11 PM | finance.yahoo.comGlobal Injectables Market is Anticipated to Surpass USD 1 Trillion Mark by 2034 | DelveInsightNovember 11, 2026 | finance.yahoo.comThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.November 17 at 1:00 AM | Digest Publishing (Ad)Hikma Pharmaceuticals : Ventures announces strategic investment in Rem3dy HealthNovember 11, 2026 | marketscreener.comMHikma Pharmaceuticals (LON:HIK) Stock Price Crosses Below 50 Day Moving Average on Analyst DowngradeNovember 11, 2026 | americanbankingnews.comBerenberg Bank Has Lowered Expectations for Hikma Pharmaceuticals (LON:HIK) Stock PriceNovember 11, 2026 | americanbankingnews.comHikma Pharmaceuticals plc Announces Appointment of Umang Vohra as Independent Non-Executive Director and Member of the Audit Committee and Nomination and Governance Committee ...November 9, 2026 | marketscreener.comMHikma Pharmaceuticals (LON:HIK) Stock Gets Price Target Trim from Deutsche Bank AktiengesellschaftNovember 9, 2026 | americanbankingnews.comSee More Headlines HIK Stock Analysis - Frequently Asked Questions How have HIK shares performed this year? Hikma Pharmaceuticals' stock was trading at GBX 1,550 at the start of the year. Since then, HIK stock has increased by 8.5% and is now trading at GBX 1,682. How do I buy shares of Hikma Pharmaceuticals? Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Hikma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hikma Pharmaceuticals investors own include Accenture (ACN), Chipotle Mexican Grill (CMG), Hudson Technologies (HDSN), Belden (BDC), Black Diamond Group (BDI), Gran Tierra Energy (GTE) and Transocean (RIG). Company Calendar Today11/17/2026Jefferies Global Healthcare Conference11/18/2026Investor update11/24/2026Status update12/16/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolLON:HIK CIKN/A Webwww.hikma.com Phone+44-20-73992760FaxN/AEmployees9,500Year FoundedN/APrice Target and Rating Average Price Target for Hikma PharmaceuticalsGBX 1,986.25 High Price TargetGBX 2,050 Low Price TargetGBX 1,870 Potential Upside/Downside+18.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)GBX 176 Trailing P/E Ratio9.56 Forward P/E RatioN/A P/E Growth2.38Net Income£353.21 million Net Margins11.31% Pretax MarginN/A Return on Equity15.05% Return on Assets9.40% Debt Debt-to-Equity Ratio77.57 Current Ratio1.98 Quick Ratio1.27 Sales & Book Value Annual Sales£3.42 billion Price / Sales1.02 Cash FlowGBX 201.71 per share Price / Cash Flow8.34 Book ValueGBX 1,027.88 per share Price / Book1.64Miscellaneous Outstanding Shares206,968,000Free FloatN/AMarket Cap£3.48 billion OptionableNot Optionable Beta0.65 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (LON:HIK) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.